ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1042

Comparison Of Medication Usage Following Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Versus Controls

Sharon Van Doornum1, Mark Tacey1, Megan Bohensky1, Caroline Brand2, Vijaya Sundararajan3 and Ian Wicks4, 1Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, 2Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia, 3Medicine, University of Melbourne, Melbourne, Australia, 4Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Autoimmune diseases and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services II & III

Session Type: Abstract Submissions (ACR)

Background/Purpose:

We have previously demonstrated that RA patients have higher post-myocardial infarction (MI) case fatality than controls [1] and that treatment with secondary prevention medications is lower in RA patients than matched controls [2].  More recently we have demonstrated that post-MI case fatality is also higher in the larger group of patients with auto-immune rheumatic disease (AIRD) such as lupus, spondyloarthritis, scleroderma and systemic necrotising vasculitis [manuscript in preparation]. The aim of this study was to compare the utilization of lipid-lowering agents (statins), beta-blockers (BB) and angiotensin converting enzyme  inhibitors (ACE-I) following MI in patients with AIRD compared to patients without AIRD.

Methods: A retrospective cohort study utilising a population-based dataset containing statewide hospital admission data linked with medication utilisation data.  Data were available from 1 July 2001 to 30 July 2009.  Cases of MI were identified from hospital admission data based on relevant International Classification of Diseases (ICD) codes. AIRD status was identified from the index MI admission or any admission in the preceding 5 years using relevant ICD codes.  Relevant co-morbidities including cardiovascular risk factors were identified using ICD codes from the index MI admission. Adjusted odds ratios (OR) for post-MI treatment with each of the specified medications in AIRD patients compared to non-AIRD patients were estimated using a logistic regression model with adjustment for age, gender, socio-economic status, geographic location and relevant co-morbidities.

Results: :  There were 21,126 individuals with an index MI, of whom 518 (2.5%) were identified as AIRD patients. The rate of statin use within 12 months post MI for patients with AIRD was 52.7% compared to 69.8% for patients without AIRD (p<0.001). A decreased rate of BB and ACE-I use was also identified for AIRD patients compared to non-AIRD patients (BB: 49.4% vs 55.6 %, p<0.005 and ACE-I: 50.2% vs 58.3%, p<0.001). The adjusted OR for statin use within 12 months post MI for AIRD patients was 0.57 (95% CI: 0.45 – 0.73). The adjusted ORs for usage of BB and ACE-I in AIRD patients within 12 months of the MI were reduced but not statistically significant after adjustment for covariates (BB: OR = 0.86, 95% CI: 0.69–1.08 and ACE-I: OR = 0.84, 0.68–1.03).

Conclusion:

Treatment with statins in the 12 months following MI is significantly lower for patients with AIRD, even after adjustment for potential confounders.  Lower rates of usage of BB and ACE-I were also found, although these differences were not statistically significant after adjustment for relevant co-variates.

[1] Van Doornum et al. 2006

[2] Van Doornum et al. 2010


Disclosure:

S. Van Doornum,
None;

M. Tacey,
None;

M. Bohensky,
None;

C. Brand,
None;

V. Sundararajan,
None;

I. Wicks,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparison-of-medication-usage-following-myocardial-infarction-in-patients-with-autoimmune-rheumatic-disease-versus-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology